 VANCOUVER, British Columbia--BUSINESS WIRE--Zymeworks Inc. NYSE: ZYME, a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 39th Annual J.P. Morgan Healthcare Conference. In addition, Zymeworks will host two webcasts in January to discuss the zanidatamab clinical data presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium ASCO GI and provide an update on ZW49s 